Anzeige
❌
Mehr »
Montag, 16.11.2026 - Börsentäglich über 12.000 News
Pelican AI: +34,75% in Frankfurt! Ist das erst der Anfang einer großen Kursrallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
OR

WKN: A14W01 | ISIN: US68628Y1047 | Ticker: OFK0
Frankfurt
13.11.26 | 08:01
51,00 Euro
0,00 % 0,00
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ORION OYJ ADR Chart 1 Jahr
5-Tage-Chart
ORION OYJ ADR 5-Tage-Chart

Aktuelle News zur ORION OYJ ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07:15Dividendenbekanntmachungen (16.11.2026)212 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ABBOTT LABORATORIES  US0028241000  0,63 USD   EUR  ABBVIE INC  US00287Y1091  1,73 USD   EUR  ASSA ABLOY AB  SE0007100581  3,2 SEK   EUR  BOARDWALK...
► Artikel lesen
ORION OYJ ADR Aktie jetzt für 0€ handeln
30.10.ORION Corp. Reveals Rise In Q3 Bottom Line17
30.10.ORION Corp. Q3 Income Rises6
28.10.Orion Oyj: Orion Group Interim report January-September 2026: Strong financial performance and positive developments in the R&D pipeline330ORION CORPORATION INTERIM REPORT 1-9/2026 28 OCTOBER 2026 at 12:00 EET Orion Group Interim report January-September 2026: Strong financial performance and positive developments in the R&D pipeline...
► Artikel lesen
26.10.Orion Oyj: Changes in Orion Group's Executive Team as of 1 January 2027446ORION CORPORATION STOCK EXCHANGE RELEASE - CHANGES BOARD/MANAGEMENT/AUDITORS 26 October 2026 at 13.00 EET Changes in Orion Group's Executive Team as of 1 January 2027 To accelerate the implementation...
► Artikel lesen
24.10.Orion Oyj: Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence1.533ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk...
► Artikel lesen
21.10.Orion Oyj Lifts FY26 Outlook619HELSINKI (dpa-AFX) - Orion Oyj (ORNBV.HE), a Nordic pharmaceutical company, Tuesday said that it is raising its fiscal 2026 net sales and operating profit outlook as royalty income has increased...
► Artikel lesen
20.10.Dividendenbekanntmachungen (20.10.2026)7.743 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  AMERICAN TOWER CORPORATION  US03027X1000  1,79 USD   EUR  ANHUI CONCH CEMENT CO LTD ADR  US0352431045  0,096 USD   EUR  ANTIN INFRASTRUCTURE...
► Artikel lesen
20.10.Orion Oyj: Inside information: Orion upgrades full-year outlook for 2026422ORION CORPORATION STOCK EXCHANGE RELEASE - INSIDE INFORMATION 20 OCTOBER 2026 at 20.20 EEST Inside information: Orion upgrades full-year outlook for 2026 Orion Corporation upgrades the full-year...
► Artikel lesen
14.10.Orion Oyj: Orion publishes Interim Report for January-September 2026 and holds a webcast on 28 October 20265
07.10.Orion Oyj: 125,000 Orion Corporation A shares converted into B shares8
06.10.Orion Pharma, Qilu Partner On Pembrolizumab Biosimilar In Europe611 HELSINKI (dpa-AFX) - Orion Corp. (0M2N.L, ORNAV.HE, ORNBV.HE) and Qilu Pharma Europe have entered into an agreement to commercialise an intravenous (IV) pembrolizumab biosimilar in Europe.Pembrolizumab...
► Artikel lesen
06.10.Orion Oyj: Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market382ORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market Orion Corporation ("Orion...
► Artikel lesen
05.10.Orion Oyj: Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company's first biologic candidate to reach clinical testing600ORION CORPORATION PRESS RELEASE 05 OCTOBER 2026 at 8:00am ET Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company's first biologic candidate to reach clinical...
► Artikel lesen
30.09.Orion Oyj: Orion Corporation completed share acquisitions2
04.09.Orion Oyj: 102,000 Orion Corporation A shares converted into B shares4
14.08.ORION Corp. Reports Higher Revenue And Profit In Q2 20261.050SEOUL (dpa-AFX) - ORION Corp. (271560.KS) on Friday reported revenue of KRW 893.59 billion for the second quarter of 2026, compared with KRW 777.17 billion in the same period of 2025. For the...
► Artikel lesen
10.08.Orion Oyj: Orion's license partner Tenax Therapeutics' Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint952ORION CORPORATION STOCK EXCHANGE RELEASE - INSIDE INFORMATION 10 AUGUST 2026 at 14.05 EEST Orion's license partner Tenax Therapeutics' Phase 3 LEVEL trial of oral levosimendan in pulmonary...
► Artikel lesen
17.07.ROUNDUP: Orion Q2 Profit Rises; Revises Outlook748HELSINKI (dpa-AFX) - (Adds Outlook)For the full year, Orion Oyj (0M2N.L) now expects operating profit of EUR 650 million to EUR 750 million, compared with the previous expectation of EUR 600...
► Artikel lesen
17.07.Orion Oyj Reveals Advance In Q2 Income787HELSINKI (dpa-AFX) - Orion Oyj (0M2N.L) reported earnings for its second quarter that Increased, from last yearThe company's bottom line came in at EUR140.2 million, or EUR1 per share. This...
► Artikel lesen
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1